Q-omics provides the consensus-scored LINC01363 profile across patient tissues and cancer cell-line models. LINC01363 expression is associated with patient survival in 15 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, LINC01363 is differentially expressed in 5, with the highest sampling consensus in HNSC. Additionally, LINC01363 RNA expression shows 6,473 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight HNSC, and STAD as cancer lineages where LINC01363 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LINC01363 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LINC01363 survival associations across molecular data types. LINC01363 RNA expression shows survival associations in the most cancer types (15). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LINC01363 RNA expression–survival associations across cancer types. High LINC01363 expression shows unfavorable associations in HNSC, ACC, BLCA, KIRC, LUSC and UVM. The HNSC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .002). Together, the overview and detailed table identify HNSC as the clearest survival context for LINC01363 RNA expression.
This table summarizes LINC01363 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 5. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for LINC01363. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LINC01363 shows lower tumor expression in KIRP and higher tumor expression in HNSC, LUSC, BRCA and LUAD. The HNSC box plot shows higher LINC01363 RNA expression in tumor versus normal tissue (log2 FC = +0.033, t-test p = .004).
This table shows molecular features associated with LINC01363 in patient tissues and cancer cell lines. In patient samples, LINC01363 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
